STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[144] Incyte Genomics Inc SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Incyte Genomics Inc (INCY) filed a Form 144 reporting a proposed sale of 277 common shares on 08/15/2025 through Morgan Stanley Smith Barney LLC. The filing lists an aggregate market value of $24,046.37 and shows 195,276,145 shares outstanding, and the shares were acquired the same day via a stock option exercise with payment in cash.

The filing also discloses five recent sales by Sheila Denton within the prior three months: 1,795 shares on 06/03/2025; 599 on 07/02/2025; 3,330 on 07/15/2025; 785 on 07/16/2025; and 598 on 08/04/2025, with gross proceeds reported for each sale. The filer certifies no undisclosed material adverse information and the form identifies Morgan Stanley as broker of record.

Positive
  • Required disclosure provided for proposed sale including broker, acquisition method, payment type, and aggregate market value
  • Recent sales history disclosed for the past three months, enhancing transparency
Negative
  • Insider selling activity by the same individual (multiple transactions totaling several thousand shares) could be viewed unfavorably by some investors
  • Form lacks issuer identity details in the provided content (issuer address and SEC file number are not shown)

Insights

TL;DR Insider exercised options and plans a small secondary sale; recent insider dispositions are disclosed but represent a tiny fraction of outstanding stock.

The filing documents a routine Form 144 tied to a same-day stock option exercise and a proposed sale of 277 shares valued at about $24k. With 195.3 million shares outstanding, the planned sale is immaterial to capitalization. Recent sales by the same individual show ongoing liquidity events but no indication of company-level disclosure issues. For investors, these are compliance-level disclosures rather than signals of operational change.

TL;DR Form 144 appears complete for the transaction and includes required past three-month sales; signature and broker details are provided.

The form lists the broker (Morgan Stanley Smith Barney LLC), acquisition method (stock option exercise), payment type (cash), and aggregates recent dispositions by the seller, satisfying Rule 144 notice elements. The filer makes the standard representation regarding material nonpublic information. No procedural or disclosure deficiencies are apparent from the text provided.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed for INCY report?

The Form 144 reports a proposed sale of 277 common shares of INCY on 08/15/2025 via Morgan Stanley, with aggregate market value $24,046.37.

How were the 277 INCY shares acquired according to the filing?

The shares were acquired on 08/15/2025 through a stock option exercise and payment was made in cash.

Who is the broker handling the proposed INCY sale?

The filing names Morgan Stanley Smith Barney LLC as the broker for the proposed sale.

What recent insider sales by the seller are reported for INCY?

The filing lists sales by Sheila Denton: 1,795 shares on 06/03/2025; 599 on 07/02/2025; 3,330 on 07/15/2025; 785 on 07/16/2025; and 598 on 08/04/2025, with gross proceeds shown for each sale.

How material is the proposed 277-share sale relative to INCY outstanding shares?

With 195,276,145 shares outstanding, the proposed sale of 277 shares is immaterial to the company’s total market capitalization.
Incyte Corp

NASDAQ:INCY

INCY Rankings

INCY Latest News

INCY Latest SEC Filings

INCY Stock Data

19.98B
191.97M
2.03%
103.47%
3.85%
Biotechnology
Services-commercial Physical & Biological Research
Link
United States
WILMINGTON